Trustmark National Bank Trust Department Maintains Stake in C.R. Bard, Inc. (BCR)
Trustmark National Bank Trust Department continued to hold its position in C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,440 shares of the medical instruments supplier’s stock at the end of the second quarter. Trustmark National Bank Trust Department’s holdings in C.R. Bard were worth $455,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Fundsmith LLP grew its stake in C.R. Bard by 2.1% during the 1st quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock worth $633,996,000 after buying an additional 52,272 shares during the last quarter. Leucadia National Corp purchased a new position in C.R. Bard during the 2nd quarter worth approximately $13,184,000. Vivaldi Asset Management LLC purchased a new position in C.R. Bard during the 2nd quarter worth approximately $57,965,000. Credit Agricole S A grew its stake in C.R. Bard by 2.8% during the 1st quarter. Credit Agricole S A now owns 89,102 shares of the medical instruments supplier’s stock worth $22,148,000 after buying an additional 2,425 shares during the last quarter. Finally, Ativo Capital Management LLC purchased a new position in C.R. Bard during the 1st quarter worth approximately $2,504,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.
A number of analysts have weighed in on BCR shares. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a research report on Tuesday, June 6th. BidaskClub cut C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. BMO Capital Markets reaffirmed a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. Finally, Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the stock. C.R. Bard currently has a consensus rating of “Hold” and a consensus price target of $292.00.
COPYRIGHT VIOLATION NOTICE: “Trustmark National Bank Trust Department Maintains Stake in C.R. Bard, Inc. (BCR)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/20/trustmark-national-bank-trust-department-maintains-stake-in-c-r-bard-inc-bcr.html.
C.R. Bard, Inc. (NYSE:BCR) traded up 0.07% during mid-day trading on Wednesday, hitting $318.50. The stock had a trading volume of 45,365 shares. The company has a 50-day moving average of $320.07 and a 200-day moving average of $299.22. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $324.58. The stock has a market cap of $23.15 billion, a price-to-earnings ratio of 41.81 and a beta of 0.60.
C.R. Bard (NYSE:BCR) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.54 earnings per share. On average, analysts anticipate that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
In other news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is currently owned by corporate insiders.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.